Inositol is a type of food additives, which plays an important role in insulin signal pathway and is related to insulin sensitivity. Our randomized, double-centered, placebo-controlled study is planned to recruit 360 pregnant women who is in high risk for gestational diabetes. They will be assumed randomly 1 g of D-chiro inositol per day or placebo from 12-16th gestational weeks until Oral Glucose Tolerance Test (OGTT) at 24-28th gestational weeks. Perinatal outcomes about delivery time, neonatal weight will be registered.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
291
Active group receives inositol 1 gram per day as well as health guidance about diet and exercise. From recruitment until OGTT.
Placebo (similar appearance but not containing myo-inositol) 1 gram per day before meals. Similar health guidance about diet and exercise. From recruitment until OGTT.
Xinning Chen
Hangzhou, Zhejiang, China
the incidence of gestational diabetes
The number of cases and incidence of gestational diabetes according to OGTT
Time frame: 24-28th weeks gestation
the perinatal outcomes-1
the incidence of macrosomia (macrosomia refers to a newborn weighs more than 4 kg)
Time frame: Delivery
the perinatal outcomes-2
weight gain during pregnancy (kg)
Time frame: Delivery
the perinatal outcomes-3
the Caesarean-section incidence (%)
Time frame: Delivery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.